ATTONasdaqManufacturing

Attovia Therapeutics, Inc. (ATTO) earnings date, market-implied expected move, and options open interest by expiry

15.05

Closed16:00 ET

Open15.91Volume146,673Mkt cap$64.4M

Day14.67 – 15.9131%52-wk12.94 – 28.0014%

ATTO

Attovia Therapeutics, Inc.

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

No implied move.

Expected move

Inputs

Next report

—

Calendar

Next report

Last report

+4.63%

shaded = implied · ▲▼ = realized

Sep 2 '26 · confirmed

Implied vs realized

Largest filed tie

—

Largest filed tie

13F top-10 QoQ

—

Top fund weight

—

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

No upcoming report date for Attovia Therapeutics (ATTO). No implied move.

Implied vs realized

1 report

—≥ implied

Q2 FY26Sep 2 '26confirmed—▲+4.63%—

quarterimplied−5%0+5%realized×

Q2 FY26—▲+4.63%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Implied vs realized

Positioning

No open-interest data.

Positioning

Linked exposure

No linked exposure.

Linked exposure

Revenue flow

Q2 FY26 · as filed

−4597.11%Q2 FY26 · as filednet margin

Revenue$450,000—

Gross profit$450,000100.00%—

Operating income−$22M−4845.11%—

Pre-tax income−$21M—

Net income−$21M−4597.11%—

Cost of revenue$0—

Operating expenses$22M—

Other income$1M—

Source: SEC filings · standardized · QE Jun 30 '26 · bars = % of revenue

Revenue flow

Intraday

15m bars

Hatch = extended hours · ▯ up · ▮ downSource: market data · 16:00 ET

Intraday

Event sensitivity

—

Earnings history

EPS -4.88 · consensus —

Quarter	Reported	EPS	Consensus
Q2 FY26	Sep 2 '26 · confirmed	-4.88	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod